Cryosite Limited (CTE) AI Stock Analysis

• Market Cap: AU$49.30M
• Dividend Yield: N/A
• Average Volume (3M): 1.97K
• Price to Earnings (P/E): 26.2
• Beta (1Y): -0.92
• Revenue Growth: 11.93%
• EPS Growth: 2.39%
• Country: AU
• Employees: 25
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.02
• Shares Outstanding: 48,809,563
• 10 Day Avg. Volume: 3,337
• 30 Day Avg. Volume: 1,969
• PEG Ratio: 8.08
• Price to Book (P/B): 15.22
• Price to Sales (P/S): 2.58
• P/FCF Ratio: 24.60
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: AU$1.00 ▼(-0.99% Downside)

Cryosite Limited's strong financial performance and positive technical indicators are offset by valuation concerns. The lack of earnings call and corporate events data limits further insights.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong demand for Cryosite's biobanking services, supporting long-term business expansion and market presence.

Profitability

High profitability margins reflect efficient operations and pricing power, which can sustain Cryosite's competitive advantage and financial health.

Market Position

Specialization in biobanking positions Cryosite as a key player in the growing regenerative medicine market, enhancing its long-term strategic position.

Negative Factors

Declining Cash Flow

Declining free cash flow growth may limit Cryosite's ability to reinvest in business opportunities, affecting future growth and financial flexibility.

Debt Reliance

While leverage is currently manageable, reliance on debt could pose risks if market conditions change, potentially impacting financial stability.

Cost Pressures

Declining gross profit margins may indicate rising costs, which could erode profitability if not managed effectively, impacting long-term margins.

Cryosite Limited Business Overview & Revenue Model

Company Description

Cryosite Limited (CTE) is a biotechnology company based in Australia that specializes in the storage and management of biological materials, particularly human tissue and stem cells. The company operates in the health and medical sectors, offering services such as cord blood and tissue banking, as well as providing biological sample storage solutions to researchers and healthcare institutions. Cryosite's core products include its proprietary biobanking services, which ensure the safe and secure preservation of valuable biological samples for future medical research and therapeutic use.

How the Company Makes Money

Cryosite Limited generates revenue primarily through its biobanking services, which involve the collection, processing, and storage of umbilical cord blood and tissue from newborns. This service typically comes with an initial fee for collection and processing, as well as ongoing annual storage fees. Additionally, the company may earn revenue from partnerships with hospitals and healthcare providers that refer clients for its biobanking services. Another key revenue stream includes providing storage solutions for research institutions and biopharmaceutical companies, which require secure storage for biological samples. The company's financial performance may also be influenced by the increasing demand for regenerative medicine and stem cell therapies, driving growth in its core offerings.

Cryosite Limited Financial Statement Overview

Summary

Cryosite Limited shows strong revenue growth and profitability with efficient operations. However, the balance sheet indicates a reliance on debt, and cash flow performance is mixed with declining free cash flow growth.

Income Statement

Cryosite Limited has demonstrated consistent revenue growth, with a notable 9.85% increase in the latest year. The company maintains strong profitability metrics, with a gross profit margin of 62.98% and a net profit margin of 13.35%. EBIT and EBITDA margins are healthy, indicating efficient operations. However, the slight decline in gross profit margin from the previous year suggests potential cost pressures.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.95, indicating manageable leverage. Return on equity is robust at 78.86%, reflecting effective use of equity to generate profits. However, the equity ratio is relatively low, suggesting a higher reliance on debt financing, which could pose risks if not managed carefully.

Cash Flow

The cash flow statement reveals a decline in free cash flow growth by 32.88%, which is a concern. The operating cash flow to net income ratio is below 1, indicating that not all earnings are being converted into cash. The free cash flow to net income ratio of 71.61% suggests a reasonable conversion of profits into free cash flow, but the declining trend in free cash flow growth warrants attention.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	12.85M	14.12M	12.61M	11.94M	11.76M	10.02M
Gross Profit	7.89M	8.89M	7.99M	6.48M	6.27M	5.31M
EBITDA	3.21M	3.41M	3.04M	2.30M	2.40M	1.65M
Net Income	1.83M	1.88M	1.84M	1.41M	1.36M	652.57K
Balance Sheet
Total Assets	19.09M	19.46M	19.71M	22.65M	21.50M	21.99M
Cash, Cash Equivalents and Short-Term Investments	4.49M	5.06M	4.70M	5.73M	5.34M	3.88M
Total Debt	2.36M	2.27M	2.44M	2.61M	849.76K	1.07M
Total Liabilities	17.77M	17.07M	18.26M	19.86M	19.64M	21.17M
Stockholders Equity	1.31M	2.39M	1.45M	2.78M	1.86M	819.23K
Cash Flow
Free Cash Flow	2.20M	1.48M	2.44M	1.19M	1.63M	80.07K
Operating Cash Flow	2.76M	2.06M	2.90M	1.49M	2.49M	476.96K
Investing Cash Flow	-561.00K	-420.00K	727.00K	-1.33M	-863.19K	-396.89K
Financing Cash Flow	-3.72M	-1.29M	-3.50M	-768.00K	-148.99K	-260.78K

Cryosite Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.01
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CTE, the sentiment is Positive. The current price of 1.01 is below the 20-day moving average (MA) of 1.07, below the 50-day MA of 1.12, and above the 200-day MA of 0.86, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 27.89 is Positive, neither overbought nor oversold. The STOCH value of 7.69 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:CTE.

Cryosite Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTE	64 Neutral	AU$49.30M	26.17	98.18%	―	11.93%	2.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LDX	50 Neutral	AU$220.42M	-17.08	-111.23%	―	12.96%	40.81%
BDX	48 Neutral	AU$38.65M	-5.15	-97.79%	―	―	23.85%
RHY	47 Neutral	AU$37.07M	-9.30	-501.54%	―	―	56.42%
MAP	41 Neutral	AU$45.67M	-2.16	-40.54%	―	29.60%	33.00%
IIQ	38 Underperform	AU$49.27M	-5.62	-37.78%	―	2.33%	12.50%

Cryosite Limited Corporate Events

Cryosite Expands Capacity with New Facility Acquisition

Cryosite Limited has completed the acquisition of a new freehold facility at Adderley Street, which more than doubles its national storage capacity. This expansion is a key part of Cryosite’s growth strategy, addressing increasing client demand and enhancing business continuity by providing additional storage space for sensitive materials. The new facility will enable Cryosite to pursue new revenue streams and expand its service offerings, including clinical trial storage, cryogenic storage, and secondary packaging. Initial works at the new site will be staged to align with client demand, ensuring operational efficiency.

Cryosite Limited Successfully Concludes Annual General Meeting with Strong Shareholder Support

Cryosite Limited held its Annual General Meeting, where all resolutions, including the adoption of the remuneration report, the company’s option plan, and the re-election of a director, were carried with significant support. This outcome reflects strong shareholder confidence in the company’s strategic direction and governance, potentially enhancing its market position and stakeholder trust.

Cryosite Limited Reports Strong Q1 FY26 Performance and Expansion Plans

Cryosite Limited reported strong financial performance in Q1 FY26, with significant revenue and profit growth driven by increased demand across its key segments. The company is expanding its operations with a new warehouse facility to enhance capacity and service offerings, while continuing to grow its client base and diversify revenue streams. The company’s leadership in temperature-controlled storage and logistics is recognized, positioning it well to meet rising demand in the industry.

Cryosite Limited Expands Capacity with Strategic Warehouse Acquisition

Cryosite Limited has announced the acquisition of a strategic warehouse facility in Auburn, NSW, marking a significant step in its growth strategy. This acquisition will more than double the company’s storage capacity, addressing current capacity constraints and enabling future revenue growth. The facility’s strategic location and operational fit will enhance Cryosite’s logistics capabilities, while the financial terms of the acquisition are favorable compared to leasing options. The expansion will also support new revenue streams and business continuity, with plans to relocate certain operations to the new site and apply for necessary regulatory approvals.

Cryosite Limited Announces 2025 Annual General Meeting

Cryosite Limited has announced its Annual General Meeting of Shareholders, scheduled for October 16, 2025, in Melbourne. The meeting notice is available electronically, and shareholders are encouraged to contact the share registry for further communications. This announcement highlights Cryosite’s commitment to maintaining transparency and engagement with its stakeholders, potentially impacting its operational strategies and industry positioning.